Celcuity announced updated Phase 1b/2 clinical trial results showing that the combination of gedatolisib and darolutamide achieved a median radiographic progression-free survival (rPFS) of 15.7 months in metastatic castration-resistant prostate cancer patients previously treated with abiraterone, and 9.1 months in those treated with enzalutamide. The treatment showed manageable safety and encouraging PSA response rates across doses. The Phase 2 study is expected to start in the first half of 2027 to further evaluate this combination in larger patient groups. This development offers a promising new treatment option for a cancer type with limited effective therapies.
The clinical trial update on gedatolisib plus darolutamide in prostate cancer patients provides context alongside Pluang's Health sector data. As of Oct 23, 2026 20:21 WIB, out of 150 priced Health-sector US stocks, only 28 rose while 119 fell. Notably, IBRX traded at USD 8.18 with a 1-day change of -1.56% and a typical hold time of 3 days, contrasting with RXRX at USD 3.53 which saw a strong buy interest of 87% and a longer hold time of 21 days, and BTSG priced at USD 60.01 with a similar 1-day decline of -1.40% and a 14-day hold time.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
